Actinium Pharma (ATNM) Prices 8M Common Stock Offering at $1.25/Share
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $1.25. In addition, Actinium has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of common stock solely to cover over-allotments, if any. The offering is expected to close on or about October 4, 2016, subject to customary closing conditions.
The gross proceeds to Actinium from this offering is expected to be $10,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Actinium. Actinium currently intends to use the net proceeds from the sale of securities for general corporate purposes, including capital expenditures, the advancement of its drug candidates in clinical trials, such as Iomab™-B and Actimab™- A, preclinical trials, and to meet working capital needs.
H.C. Wainwright & Co. is acting as sole book-running manager for the offering. JonesTrading Institutional Services LLC is acting as co-manager for the offering. ROTH Capital is acting as a financial advisor for the offering.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Actinium Pharmaceuticals Announces New Hires As Supply Chain Organization Expands To Accommodate Growth
- Gilat Satellite's (GILT) Satellite-Based Cellular Backhaul Solution Selected for Use by Sprint (S)
- Actinium Pharma (ATNM) Commences EMA Scientific Advice Process for Iomab-B
Create E-mail Alert Related CategoriesCorporate News, Equity Offerings, Hot Corp. News
Related EntitiesRoth Capital, H.C. Wainwright
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!